Second line therapy with axitinib after only prior sunitinib in metastatic renal cell cancer: Italian multicenter real world SAX study final results

BACKGROUND: This multi-institutional retrospective real life study was conducted in 22 Italian Oncology Centers and evaluated the role of Axitinib in second line treatment in not selected mRCC patients. METHODS: 148 mRCC patients were evaluated. According to Heng score 15.5%, 60.1% and 24.4% of pati...

Full description

Saved in:
Bibliographic Details
Published in:J Transl Med
Main Authors: Facchini, Gaetano, Rossetti, Sabrina, Berretta, Massimiliano, Cavaliere, Carla, Scagliarini, Sarah, Vitale, Maria Giuseppa, Ciccarese, Chiara, Di Lorenzo, Giuseppe, Palesandro, Erica, Conteduca, Vincenza, Basso, Umberto, Naglieri, Emanuele, Farnesi, Azzurra, Aieta, Michele, Borsellino, Nicolò, La Torre, Leonardo, Iovane, Gelsomina, Bonomi, Lucia, Gasparro, Donatello, Ricevuto, Enrico, De Tursi, Michele, De Vivo, Rocco, Lo Re, Giovanni, Grillone, Francesco, Marchetti, Paolo, De Vita, Ferdinando, Scavelli, Claudio, Sini, Claudio, Pisconti, Salvatore, Crispo, Anna, Gebbia, Vittorio, Maestri, Antonio, Galli, Luca, De Giorgi, Ugo, Iacovelli, Roberto, Buonerba, Carlo, Cartenì, Giacomo, D’Aniello, Carmine
Format: Artigo
Language:Inglês
Published: BioMed Central 2019
Subjects:
Research
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6716812/
https://ncbi.nlm.nih.gov/pubmed/31464635
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12967-019-2047-4
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items